edit-301,dostarlimab
gsk,editas medicine, inc.
['ruby', 'dostarlimab', 'gyn']
dostarlimab reduced the risk of progression by 34% in patients with advanced/recurrent endometrial cancer overall and by 71% in patients with dmmr/msi-h disease. results from the ruby trial. #asco23 #gyncsm 
https://t.co/bi63MIVP5D is a resource offering oncology health care professionals practical information about the changing clinical landscape.